JANX
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) has 9 SEC Form 4 filings (9 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 11, 2026.
- Industry:Biotechnology
- CEO:David Alan Campbell
- Employees:91
- HQ:San Diego, CA, US
- IPO:2021-06-11
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$57K
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$966.0M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Doyle Janeen NoelFirst filing | Chief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $57K | Jun 5 | SEC ↗ |
Related companies
Janux Therapeutics, Inc. is in the Healthcare sector.